Clinical Trials Logo

Clinical Trial Summary

Many osteosarcomas are cured with a variety of combined chemotherapy and surgery, but a significant number will still relapse.VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer.We aimed to explore the efficacy and safety of fruquintinib combined immunotherapy for bone and soft tissue sarcoma.


Clinical Trial Description

A single-arm, open-label, single-center prospective study of fruquintinib combined with envafolimab in the treatment of advanced or unresectable locally advanced bone and soft tissue sarcoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05941325
Study type Interventional
Source Shanghai 6th People's Hospital
Contact
Status Recruiting
Phase Phase 2
Start date April 1, 2023
Completion date December 1, 2026